Mikkel Staberg1, Signe Regner Michaelsen2, Rikke Darling Rasmussen3, Mette Villingshøj2, Hans Skovgaard Poulsen2, Petra Hamerlik4. 1. Department of Radiation Biology, The Finsen Center, Rigshospitalet, Copenhagen, Denmark. mikkel.staberg@regionh.dk. 2. Department of Radiation Biology, The Finsen Center, Rigshospitalet, Copenhagen, Denmark. 3. Brain Tumor Biology Group, Danish Cancer Society Research Center, Copenhagen, Denmark. 4. Brain Tumor Biology Group, Danish Cancer Society Research Center, Copenhagen, Denmark. pkn@cancer.dk.
Abstract
PURPOSE: Glioblastoma (GBM) ranks among the deadliest solid cancers worldwide and its prognosis has remained dismal, despite the use of aggressive chemo-irradiation treatment regimens. Limited drug delivery into the brain parenchyma and frequent resistance to currently available therapies are problems that call for a prompt development of novel therapeutic strategies. While only displaying modest efficacies as mono-therapy in pre-clinical settings, histone deacetylase inhibitors (HDACi) have shown promising sensitizing effects to a number of cytotoxic agents. Here, we sought to investigate the sensitizing effect of the HDACi trichostatin A (TSA) to the alkylating agent lomustine (CCNU), which is used in the clinic for the treatment of GBM. METHODS: Twelve primary GBM cell cultures grown as neurospheres were used in this study, as well as one established GBM-derived cell line (U87 MG). Histone deacetylase (HDAC) expression levels were determined using quantitative real-time PCR and Western blotting. The efficacy of either CCNU alone or its combination with TSA was assessed using various assays, i.e., cell viability assays (MTT), cell cycle assays (flow cytometry, FACS), double-strand DNA break (DSB) quantification assays (microscopy/immunofluorescence) and expression profiling assays of proteins involved in apoptosis and cell stress (Western blotting and protein array). RESULTS: We found that the HDAC1, 3 and 6 expression levels were significantly increased in GBM samples compared to non-neoplastic brain control samples. Additionally, we found that pre-treatment of GBM cells with TSA resulted in an enhancement of their sensitivity to CCNU, possibly via the accumulation of DSBs, decreased cell proliferation and viability rates, and an increased apoptotic rate. CONCLUSION: From our data we conclude that the combined administration of TSA and CCNU eradicates GBM cells with a higher efficacy than either drug alone, thereby opening a novel avenue for the treatment of GBM.
PURPOSE:Glioblastoma (GBM) ranks among the deadliest solid cancers worldwide and its prognosis has remained dismal, despite the use of aggressive chemo-irradiation treatment regimens. Limited drug delivery into the brain parenchyma and frequent resistance to currently available therapies are problems that call for a prompt development of novel therapeutic strategies. While only displaying modest efficacies as mono-therapy in pre-clinical settings, histone deacetylase inhibitors (HDACi) have shown promising sensitizing effects to a number of cytotoxic agents. Here, we sought to investigate the sensitizing effect of the HDACi trichostatin A (TSA) to the alkylating agent lomustine (CCNU), which is used in the clinic for the treatment of GBM. METHODS: Twelve primary GBM cell cultures grown as neurospheres were used in this study, as well as one established GBM-derived cell line (U87 MG). Histone deacetylase (HDAC) expression levels were determined using quantitative real-time PCR and Western blotting. The efficacy of either CCNU alone or its combination with TSA was assessed using various assays, i.e., cell viability assays (MTT), cell cycle assays (flow cytometry, FACS), double-strand DNA break (DSB) quantification assays (microscopy/immunofluorescence) and expression profiling assays of proteins involved in apoptosis and cell stress (Western blotting and protein array). RESULTS: We found that the HDAC1, 3 and 6 expression levels were significantly increased in GBM samples compared to non-neoplastic brain control samples. Additionally, we found that pre-treatment of GBM cells with TSA resulted in an enhancement of their sensitivity to CCNU, possibly via the accumulation of DSBs, decreased cell proliferation and viability rates, and an increased apoptotic rate. CONCLUSION: From our data we conclude that the combined administration of TSA and CCNU eradicates GBM cells with a higher efficacy than either drug alone, thereby opening a novel avenue for the treatment of GBM.
Entities:
Keywords:
Epigenetics; Glioblastoma; HDACi; Lomustine; Sensitization; Trichostatin A
Authors: H Sawa; H Murakami; Y Ohshima; T Sugino; T Nakajyo; T Kisanuki; Y Tamura; A Satone; W Ide; I Hashimoto; H Kamada Journal: Brain Tumor Pathol Date: 2001 Impact factor: 3.298
Authors: Wolfgang Wick; Vinay K Puduvalli; Marc C Chamberlain; Martin J van den Bent; Antoine F Carpentier; Lawrence M Cher; Warren Mason; Michael Weller; Shengyan Hong; Luna Musib; Astra M Liepa; Donald E Thornton; Howard A Fine Journal: J Clin Oncol Date: 2010-02-01 Impact factor: 44.544
Authors: W Weichert; A Röske; V Gekeler; T Beckers; C Stephan; K Jung; F R Fritzsche; S Niesporek; C Denkert; M Dietel; G Kristiansen Journal: Br J Cancer Date: 2008-01-22 Impact factor: 7.640
Authors: Concha López-Ginés; Lara Navarro; Lisandra Muñoz-Hidalgo; Enrique Buso; José Manuel Morales; Rosario Gil-Benso; Mariela Gregori-Romero; Javier Megías; Pedro Roldán; Remedios Segura-Sabater; José Manuel Almerich-Silla; Daniel Monleón; Miguel Cerdá-Nicolás Journal: Cell Oncol (Dordr) Date: 2017-06-19 Impact factor: 6.730
Authors: Renata L Markman; Liana P Webber; Carlos H V Nascimento Filho; Leonardo A Reis; Pablo A Vargas; Marcio A Lopes; Virgilio Zanella; Manoela D Martins; Cristiane H Squarize; Rogerio M Castilho Journal: Cell Oncol (Dordr) Date: 2018-12-11 Impact factor: 6.730